CinCor Pharma, Inc., Doses First Patient in HALO, a Phase 2 Clinical Trial Evaluating CIN-107, a Selective Aldosterone Synthase Inhibitor, in Patients with Uncontrolled Hypertension and High Plasma Aldosterone
09 déc. 2021 08h00 HE
|
CinCor Pharma, Inc.
CINCINNATI, Dec. 09, 2021 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”), announced today the dosing of the first patient in its Phase 2 clinical trial evaluating CIN-107, a highly selective,...
CinCor Pharma Announces First Patient Dosed with CIN-107 in Phase 2 Study in Treatment Resistant Hypertensive Subjects
20 oct. 2020 08h00 HE
|
CinCor Pharma, Inc.
CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company developing medications targeting cardiovascular disease, announced today that...
Marina Biotech Announces a New Publication on Prestalia®
27 févr. 2018 10h15 HE
|
Marina Biotech, Inc.
City of Industry, CA, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics...
Marina Biotech Announces Agreement for Drug Development and Licensing with Autotelic Bio
16 janv. 2018 08h40 HE
|
Marina Biotech, Inc.
City of Industry, CA, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics...
Marina Biotech Appoints Isaac Blech to its Board of Directors
27 nov. 2017 08h30 HE
|
Marina Biotech, Inc.
City of Industry, CA , Nov. 27, 2017 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics...